Immunomedics Inc. (NASDAQ:IMMU) shares rose 2.5% on Wednesday . The stock traded as high as $2.88 and last traded at $2.87, with a volume of 957,573 shares. The stock had previously closed at $2.80.

IMMU has been the topic of several recent analyst reports. Jefferies Group raised shares of Immunomedics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $1.50 to $5.00 in a research note on Friday, May 6th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Immunomedics in a research note on Tuesday, May 24th.

The firm’s 50-day moving average price is $2.59 and its 200 day moving average price is $2.86. The company’s market cap is $272.09 million.

Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.06. On average, equities research analysts expect that Immunomedics Inc. will post ($0.57) EPS for the current year.

In other news, CEO Cynthia L. Goldenberg sold 371,990 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $3.03, for a total value of $1,127,129.70. Following the completion of the transaction, the chief executive officer now owns 650,396 shares of the company’s stock, valued at $1,970,699.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cynthia L. Goldenberg sold 41,441 shares of the company’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $3.62, for a total value of $150,016.42. Following the completion of the transaction, the chief executive officer now directly owns 703,029 shares of the company’s stock, valued at approximately $2,544,964.98. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Immunomedics stock. Marshall Wace LLP acquired a new stake in shares of Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned approximately 0.90% of Immunomedics as of its most recent SEC filing.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.